HBsAg inhibitor (ZhiMeng Biopharma)

N/A

Report date: 2025/03/20 15:46:29
NME

Base Information

Drug NameHBsAg inhibitor (ZhiMeng Biopharma)
Drug Alias Nameanti-HBsAg small molecule therapy (ZhiMeng Biopharma)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Zhimeng Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Zhimeng Biopharma Inc
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A